Noxilizer Acquires Japanese-Based Saian Corporation Assets and Expands Nitrogen Dioxide Sterilization Product Line for Global Life Science Marketplace
Nitrogen dioxide (NO2) sterilization technology represents one of the more important innovations in medical device sterilization in over 20 years. As a room temperature sterilization alternative to ethylene oxide (EO), gamma and hydrogen peroxide, Noxilizer provides an option for companies to save significant costs by safely sterilizing in house, allowing inventory release in just hours versus days. Other benefits provided by nitrogen dioxide sterilization include: a true room temperature process, improved materials compatibility, much faster cycle time and no concerns about residuals. All important factors as pharmaceutical, biotech and medical device companies continue to innovate and grow.
“Noxilizer’s acquisition of SAIAN Corporation assets will immediately bring an expanded line of NO2 sterilization products to our customers in the pharmaceutical, biotech and medical device markets. SAIAN’s unique approach to providing sterilizers with on- board sterilant generation and abatement capability offers great advantages in room temperature sterilization which we believe will greatly benefit our customers. We are excited about the opportunity to introduce breakthrough sterilization technology as a means to improve customer productivity and build shareholder value. The agreement also establishes Noxilizer as a global player in the life science sterilization market, including the important Japanese market,” says Lawrence Bruder, President & CEO of Noxilizer, Inc.
“We are very excited to bring a strong product contribution to Noxilizer. Noxilizer has already developed a presence in the market and is generating revenue. The engineering team in Japan looks forward to working together,” says Ryuichi Iwasaki, formerly CEO of SAIAN and now General Manager, Noxilizer Japan KK. Ryuichi Iwasaki will lead the team in Japan and report to Lawrence Bruder.
SAIAN Corporation’s leading investor since inception is The University of Tokyo Edge Capital Co., Ltd. based in Tokyo, Japan. “We believe in the power of nitrogen dioxide sterilization and the ability to impact the pharmaceutical, biotech and medical device markets. The potential for both companies to be successful increases when they work as one. Our investment team has great confidence in the leadership and looks forward to continuously investing in the potential of nitrogen dioxide sterilization enabled by Noxilizer and combined with SAIAN assets, together with a wider range of investment groups in the US and Japan,” says Tomotaka (Tommy) Goji, Managing Partner & President of UTEC.
Noxilizer’s headquarters will continue to be in Baltimore, MD. Noxilizer Japan KK is a newly formed subsidiary located in Wakayama-shi, Japan.
About Noxilizer, Inc.:
Noxilizer has a unique and superior NO2-based sterilization technology that is revolutionizing two major sterilization markets — pharmaceutical/biotechnology/medical device manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for next generation medical devices and drug/device combination products. Noxilizer also sells the RTS 360 Industrial NO2 Sterilizer to companies that sterilize their own products. In hospitals, Noxilizer is developing a system especially for the sensitive, high-tech equipment used in minimally-invasive surgical procedures. The company was founded in 2004 and is privately held. Investors include: CHV Capital in Indiana, Maryland Healthcare Product Development Corporation and the University of Tokyo Edge Capital Co., Ltd. (UTEC), as well as angel investors. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD and Wakayama-shi, Japan.
Media Contact:
Angela S. Kearns
Noxilizer, Inc.
C (574) 304-1502
akearns@noxilizer.com